Liberty One Investment Management LLC Has $4.98 Million Position in Medtronic PLC $MDT

Liberty One Investment Management LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 3.5% in the second quarter, HoldingsChannel.com reports. The firm owned 57,155 shares of the medical technology company’s stock after purchasing an additional 1,907 shares during the quarter. Liberty One Investment Management LLC’s holdings in Medtronic were worth $4,982,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in Medtronic during the 1st quarter valued at approximately $26,000. Columbia River Financial Group LLC acquired a new stake in Medtronic during the 1st quarter valued at approximately $28,000. Twin Tree Management LP acquired a new stake in Medtronic during the 1st quarter valued at approximately $29,000. Activest Wealth Management increased its position in Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares during the period. Finally, Hughes Financial Services LLC acquired a new stake in Medtronic during the 1st quarter valued at approximately $32,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Transactions at Medtronic

In other Medtronic news, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The disclosure for this sale can be found here. 0.26% of the stock is owned by company insiders.

Medtronic Trading Up 0.2%

Shares of Medtronic stock opened at $95.97 on Tuesday. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The firm has a market cap of $123.10 billion, a PE ratio of 26.44, a P/E/G ratio of 2.52 and a beta of 0.78. The stock has a fifty day moving average price of $94.13 and a 200-day moving average price of $89.08. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion during the quarter, compared to analyst estimates of $8.37 billion. During the same period last year, the firm posted $1.23 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date was Friday, September 26th. Medtronic’s payout ratio is currently 78.24%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Truist Financial increased their target price on shares of Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research report on Wednesday, October 15th. UBS Group increased their price target on Medtronic from $94.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Morgan Stanley restated an “overweight” rating and set a $107.00 price target (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. Royal Bank Of Canada restated an “outperform” rating and set a $111.00 price target on shares of Medtronic in a report on Friday, October 10th. Finally, Citigroup increased their price target on Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $102.82.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.